Direct Meds review

Direct Meds prices sublingual semaglutide at $249 a month and the injection at $297; tirzepatide is $299 sublingual and $399 injectable. Those four figures are accurate as published, but none of them is a one-month decision — each carries a three-month commitment.

That commitment is the thing the marketing copy obscures. On each of the four product pages the only plan actually offered in the selector is a 90-day option billed monthly, and each one's own checkout data marks it as a subscription with a three-month commitment. So the smallest sum you can agree to is $747 for sublingual semaglutide, $891 for the semaglutide injection, $897 for sublingual tirzepatide, or $1,197 for the tirzepatide injection. Carried across a full year those rates come to $2,988, $3,564, $3,588 and $4,788.

That sits awkwardly next to Direct Meds' own words. The weight-loss page says "what you see is what you pay — no subscriptions, no surprise charges, and no pressure," and the product pages advertise cancel-anytime terms. The underlying plan data on those same pages says subscription, with a three-month commitment. Both statements are on the site right now. Get the cancellation terms confirmed in writing before your first charge, because the copy and the plan do not agree.

Two smaller ambiguities are worth carrying with you. Every headline reads "as low as," which makes each figure a floor rather than a set price. And the product pages advertise 30, 90, 180 or 360 day supplies as a feature, while only the 90-day option was actually selectable on any of the four when they were read on August 28, 2026. There is also a wrinkle in what a month means here: the internal product codes describe an 84-day, twelve-week block while the label being sold reads "90 Day Supply." Which one governs cannot be settled from the public pages, so it is a fair question to put to support before you enroll rather than after.

The reason to look at Direct Meds is format. It runs a sublingual route alongside the injection on both molecules, which few providers do, and the sublingual option is the cheaper of the two on each — $249 against $297 on semaglutide, $299 against $399 on tirzepatide. Direct Meds' own support article confirms the sublingual tirzepatide is $299 per bottle regardless of dose or strength, a 30-day supply with free shipping, so escalating your dose does not escalate the bill. Shipping is free, there is no monthly membership on top, and the site states that nurse support, shipping and digital follow-ups are bundled into the rate. Bulk pricing on 6- and 12-month plans is mentioned but not priced, and HSA and FSA payments are accepted.

Two gaps. Direct Meds does not publish which states it serves, so eligibility is something you discover during intake. And everything here is compounded, with no FDA-approved brand-name route — the usual trade for this price band, but worth naming.

One matter of public record before you decide: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We are not going to characterize what that letter alleges, because putting an enforcement action into our own words would turn a citable fact into an accusation, and the letter is published in full in the FDA's warning letter database for you to read. It does not remove Direct Meds from this page and it has not changed the link. It is disclosure, not a verdict.

This works for someone who wants a needle-free sublingual route on either molecule at a flat per-dose price, expects to be on treatment for at least a quarter anyway, and would rather pay one bundled rate than a medication charge plus a membership. It works badly for anyone who wants to try a month and stop, anyone who needs to confirm state coverage before starting an intake, and anyone who wants brand-name product. If you do enroll, go in knowing you are committing to three months at the rate you see — and ask what happens in month four.